AllDocs -> cancers

1 3-D Visualization and Analysis in Prostate Cancer Richard A. Robb, Ph.D. Scheller Professor in Medical Research Mayo Foundation/Clinic Introduction and Background The practice of medicine and conduct of clinical interventions have always relied upon visualizations to study and understand the relationship of anatomic structure to biologic function, to detect and characterize pathology and injury, and to deliver timely and effective therapy. However, most current medical interventional procedures (e.g., surgery, biopsy, ablation) still require “blind” approaches (i.e., the clinicians cannot directly see the target and/or pathway to the target during the procedure), or if visualizations are available, they are often limited to 2D, slow and/or off-line displays. These procedures also often depend on gross approximations and estimates of target position and orientation and may be ...

IV. Prostate Cancer Research Program Page 2 Prostate Cancer Research Program IV-2 Vision: To conquer prostate cancer . Mission: To promote innovative, multidisciplinary, and regionally focused research directed toward eliminating prostate cancer . Congressional Appropriations for Peer Reviewed Research: ¦ $395M in FY97–02 ¦ $85M in FY03 ¦ $85M in FY04 Funding Summary: ¦ 797 awards from the FY97–02 appropriations ¦ 216 awards from the FY03 appropriation ¦ 2om the FY04 appropriation The Disease Prostate cancer is the most commonly diagnosed cancer in men, accounting for 33% of all cancers in men. In 2004, approximately 230,110 men in the United States will be diagnosed with ...

Principal Investigator/Program Director (Last, first, middle): Hersh, Louis B. PHS 398 (Rev. 05/01) Page 187 Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. Project 5: Dissecting the Cell Surface Proteome of Prostate Cancer PI: Haining Zhu, Ph.D. Mentor: Natasha Kyprianou, Ph.D. Co-mentor Tom Vanaman, Ph.D. No human subjects or human subject materials involved in this project. No Vertebrate animals will be used in this project. Page 2 Principal Investigator/Program Director (Last, first, middle): Hersh, Louis B. PHS 398 (Rev. 05/01) Page 187 Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. DESCRIPTION: State the application’s broad, long-term objectives and specific aims, making ...

1 1 I NVESTIGATION OF M ETASTATIC B ONE D ISEASE IN N EWLY D IAGNOSED P ROSTATE C ANCER U SING N UCLEAR M EDICINE T ECHNIQUES I NVESTIGATION OF M ETASTATIC B ONE D ISEASE IN N EWLY D IAGNOSED P ROSTATE C ANCER U SING N UCLEAR M EDICINE T ECHNIQUES Reviewed 2003 Scope This guidelines refers to the investigation of the presence of metastatic bone disease in newly diagnosed prostate cancer using nuclear medicine bone scans. It does not address the use of bone scans in patients already diagnosed with metastatic ...

HTA in Norway Newsletter from The Norwegian Centre for Health Technology Assessment Nr.1 2002 Implantable defibrillator Content Implantable defibrillator 2 Brachytherapy and prostate cancer .. 3 HTA in Norway is published by the Norwegian Centre for Health Technology Assessment (SMM). The main task for the centre is to critically review the scientific basis for new and existing methods in Norwegian health services Editor in chief: Berit Mørland Editor: Dagny Fredheim SMM SINTEF Unimed P.Box 124 Blindern 0314 Oslo Norway T: 47 22 06 79 61 F: 47 22 06 79 79 E-mail: smm@unimed.sintef.no Internet: http://www.sintef.no/smm ISSN1502-119X Brachytherapy and prostate cancer SMM has published a report on the possible benefits of implantable defibrillators. The treatment has a significant beneficial effect on ...

601 S. Carlin Springs Road Arlington, VA 22204 Phone: (703) 671-1200 Fax: (703) 578-2281 Website: www.nvchospital.com A Consumer’s Guide To Understanding Prostate Cancer Serving as a beacon of Serving as a beacon of strength and leadership, strength and leadership, NVCH will provide a NVCH will provide a seamless, integrated seamless, integrated health care delivery system health care delivery system that meets the needs of that meets the needs of our community for high our community for high quality, cost-effective and quality, cost-effective and accessible care. Vision To be a pillar of security To be a pillar of security and trustworthiness, and trustworthiness, providing quality health providing quality health ...

WHAT EVERY MAN SHOULD KNOW ABOUT PROSTATE CANCER By Stephen B. Strum, MD, FACP and Donna Pogliano, co-authors of “A Primer on Prostate Cancer , The Empowered Patient’s Guide” with collaboration from UK resident, John Inchley If someone in your family had prostate cancer or breast cancer , then you are more likely to get prostate cancer . Prostate cancer can have no signs, so it is important that you should be tested every year from the age of 50. Testing is done in two parts – 1. The PSA blood test. A PSA of 3 or more should be checked to rule out cancer . A PSA that keeps rising, even if it is still below 3, should also be checked. Prostate cancer is easier to deal with if it is caught early. 2. The DRE (digital rectal exam). This is a simple test to feel and check the prostate . If you are not given a DRE, you should ask for it to be done as it can help find cancer that ...

June 1, 2004 Atrix Updates Eligard ® Prostate Cancer Products in Latin America Fort Collins, CO (June 01, 2004) -- Atrix Laboratories, Inc. (NASDAQ NM: ATRX) announced today that Tecnofarma International Ltd., Atrix's Latin America licensee, received marketing authorization from the Mexican regulatory authorities for the company's one- and three-month prostate cancer products. Eligard 7.5mg (leuprolide acetate for injectable suspension) one month prostate cancer product was launched in May. Eligard® 7.5mg and 22.5mg (leuprolide acetate for injectable suspension) are indicated for the palliative treatment of hormone sensitive advanced prostate cancer . "We estimated the private market in Mexico to be approximately $4 million. However, regardless of the size of the market, it is our goal to make Eligard a global product and give access to this new treatment option for prostate cancer patients ...

December 15, 2003 Eligard® Prostate Cancer Products Receive Approval in Australia Fort Collins, CO (December 16, 2003) -- Atrix Laboratories, Inc. (NASDAQ NM: ATRX) announced today that Mayne Pharmaceutical, Atrix's licensee, has received marketing approval of Eligard® (leuprolide acetate for injectable suspension) one-, three- and four-month prostate cancer product in Australia from the Australian Drug Evaluation Committee. "We continue to make great progress in making Eligard available around the world as a new choice in hormone therapy for men with advanced prostate cancer ," said David R. Bethune, Atrix's chairman & chief executive officer. "Currently, Eligard is marketed in the U.S. and Argentina, with recent approvals in Canada, Germany, and now Australia. This latest approval validates Atrix's confidence in the long-term value of the Eligard product line." Bethune continued, "With this ...

November 7, 2003 Eligard® Prostate Cancer Products Approved in Canada Fort Collins, CO (November 07, 2003) -- Atrix Laboratories, Inc. (NASDAQ NM: ATRX) announced today that Sanofi-Synthelabo Canada, Atrix's licensee, has received notice of compliance (NOC) from the Therapeutic Products Directorate of Health Canada for Eligard® 7.5mg and 22.5mg (leuprolide acetate for injection), one- and three-month sustained-release prostate cancer products. NOC permits these products to be sold in Canada. Sanofi-Synthelabo Canada will be responsible for marketing the products in Canada. "As director of technical affairs, it is my responsibility to leverage our core U.S. New Drug Application to build a worldwide franchise for Eligard," said Elyse Wolff, director of technical affairs. "This is the first ex-U.S. approval and we look forward to repeating this success throughout the world." The Canadian market opportunity ...

November/December 2004, Vol. 11, No. 6 364 Cancer Control Introduction Prostate cancer is the most common cancer of men in the United States. In 2004,an estimated 230,110 cases will be diagnosed and 29,900 men will die of prostate cancer . 1 The majority of patients who are diagnosed with localized prostate cancer are treated for cure with either radiation or surgery. Patients in whom treatment with curative intent is unsuccessful and those who present with metas- tasis are candidates for androgen suppression. The medi- an duration of time to progression (TTP) while on this “primary”hormone therapy is 14 to 30 months. 2 Management of Androgen-Independent Prostate Cancer Michael Diaz, MD, and Stephen G. Patterson, MD Background: Although androgen withdrawal can control prostate cancer for long periods in many patients, ...

Owen Sound Prostate Cancer Support Group Notice Of Meeting A support group that provides understanding, hope, and information to prostate cancer patients and their families. Date: Place Time: Programme: July 21st 04 St Andrews Presbyterian Church 7pm Social / 7.30 meeting Round Table Page 2 Member of USTOO and CPCP and supported by the Canadian Cancer Society Chairman: Colin Campbell 519-371-4779 V/Chair & Secy: F Butler 519 372 1619 Dear Friends; I hope you are having a pleasant time this summer although it has been cool so far! Our immediate goal is to consider what we as a group can do to increase awareness in the general public of the threat which Prostate Cancer poses.The Federal Government has withdrawn special funding for Pca research while maintaining ...

About prostate cancer • Prostate cancer is the second most common cause of cancer death in UK men. • It is mainly a cancer of older men. Only 1 in 20 cases occur in men under 60. • The number of new cases increased rapidly in the 1990s.This was largely because greater use of the ‘PSA test’ (see box) led to more cases of prostate cancer being detected. • A small number of men have a much higher than average risk of prostate cancer because they inherited a faulty gene from a parent. • By the age of 80, more than half of all men have cancerous changes in their prostate . However, the disease often grows very slowly without causing problems. Many men never know they have it and will die of unrelated causes. • The highest rate of prostate cancer in the world is in men of African descent. The lowest rates are in Far Eastern ...

P ROSTATE C ANCER S CREENING States with Laws Mandating Prostate Cancer Screening Coverage (through March 31, 2002) Twenty-six states have enacted laws that mandate third- party coverage for prostate cancer screening. The laws in these states require specified insurers to provide coverage for certain prostate cancer screening exams. Notably, the law in Oklahoma requires only the offer of coverage by cer- tain insurers. The benefits of screening for prostate cancer are currently being studied. Scientists at the National Cancer Institute are studying ways to improve the reliability of the prostate - specific antigen (PSA) test. Scientists are also studying the value of early prostate cancer detection by the PSA test and digital rectal examination (DRE) on reducing the number of deaths caused by prostate ...

Ten states now have prostate cancer -related laws, all of which have been enacted since 1990. Most of these laws require insurers to provide coverage for prostate cancer screening tests. Others address quality assurance of the tests, provision of information about prostate cancer treatment, and building public awareness about prostate cancer . P ROSTATE C ANCER L AWS Reimbursement for Prostate Cancer Screening Tests Quality Assurance of Prostate Cancer Screening Tests Seven states have laws requiring specified group and individual insurers to provide coverage for prostate cancer screening tests, including prostate -specific antigen (PSA) tests and digital rectal examinations. Most of these states require that coverage be provided for men within specified age groups (see table below) . ...

1 A MARINE’S PROSTATE CANCER JOURNAL By John Van Nortwick I am posting this journal that records my experiences with prostate cancer in the hope that it will help one or more of the Marines or other Vietnam Vets out there. While it may be preaching to the choir for many whom have already been thru this, I feel that if I can help just one of you who is facing the same situation I did, then it will be well worth the effort. The possible relationship between Vietnam service, Agent Orange, and prostate cancer makes it even more important to post this. The increasing number of deaths of so many Popasmoke members from cancer in the recent past only reinforces this more. I do not pretend to say that we did the right things or the wrong things, just stating the things we did. I use the term “we” and “us” because my wife, Sonja, who many of you know, was beside me every step of the way, providing ...

Agricultural Health Study 2003 Prostate Cancer and Agricultural Pesticides Iowa Office: The University of Iowa 100 Oakdale Campus Iowa City, IA 52242-5000 Collaborating Partners: Iowa State University Extension Iowa Department of Agriculture and Land Stewardship 1-800-217-1954 www.aghealth.org Risk of prostate cancer increases with frequent use of methyl bromide. The Agricultural Health Study seeks to identify factors that promote good health. rostate cancer is the most common cancer (other than nonmelanoma skin cancer ) in Iowa men. Despite its common occurrence, we know little about its causes. The most consistent risk factors reported are age, family history, African-American ethnicity, and hormonal factors. Farming has been the most consistent ...

EFFECTIVENESS EFFECTIVENESS Matters Matters NHS CENTRE FOR REVIEWS AND DISSEMINATION Effectiveness Matters is an update on the effectiveness of health interventions for practitioners and decision makers in the NHS. It is produced by researchers at the NHS Centre for Reviews and Dissemination at the University of York, based on high quality systematic reviews of the research evidence. Effectiveness Matters is extensively peer reviewed by subject area experts and practitioners. The NHS Centre for Reviews and Dissemination is funded by the NHS Executive and the Health Departments of Scotland, Wales and Northern Ireland; a contribution to the Centre is also made by the University of York. The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive or the Health Departments of Scotland, Wales or Northern Ireland. ...

Cancer in Rhode Island 13-1 PROSTATE CANCER Prostate cancer begins as a tumor in the prostate gland of the urinary tract. It may spread to other areas of the body. Enlargement of the prostate is often normal for men, especially as they age. However, abnormal enlargement can be the result of a malignant tumor. (RICAN) Prostate cancer is the most commonly diagnosed cancer among RI males (average annual of 850 newly diagnosed cases in each of the five years 1997-2001), and accounted for 14% of all newly diagnosed cancers in 1997-2001, including both males and females. Prostate cancer is the second leading cause of cancer death among RI males (average annual of 140 deaths in each of the five years 1996-2000), and accounted for 6% of all cancer deaths in 1996-2000, including both males and females. In Rhode Island, about 5,918 males alive today were diagnosed with prostate cancer ...

Patient Handout Primer on Prostate Cancer According to the National Cancer Institute, prostate cancer is the second most common cancer affecting men in America.All men are at risk for prostate cancer , but the risk is highest for black men over age 65. Symptoms of prostate cancer include: • needing to urinate often; • not being able to urinate; • trouble starting to urinate or holding it back; • weak or stop-and-go flow; • pain or burning when urinating; • blood in urine or semen; • painful ejaculation; and • regular pain in lower back, hips or upper thighs. These symptoms are not only caused by prostate cancer , however. They also can be caused by medical problems that are not as serious.Tell your doctor right away if you have any of these symptoms. What Is the Prostate ? The prostate is a gland in a man’s repro- ductive ...

P Prostate 1250 4” street Cancer Santa Monica, CA 90401 Telephone [310]570-4711 Foundation sum/e [3 10]570-4694 www prolatcancerfoundtion.or LESLIE D. MICHELSON lilce Chawman and Chief Executive Ojicer July 30, 2004 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Submitter: Leslie D. Michelson Organization: Prostate Cancer Foundation Re: Critical Path Initiative (Docket No. 2004N-018 1, 69 Federal Register, 2 1839, April 22, 2004); Establishment of a Docket Dear Madam/Sir: The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research. In the decade since it was founded, The PCF has invested over $150 million to support more than 1,100 research programs ...

Questions & Answers About The Genetics of Prostate Cancer Study Dr. William J. Catalona What is the study? The purpose of the study is to examine the genetic causes of prostate cancer , as well as what genetic factors may determine the aggressiveness of prostate cancer (how quickly it spreads). In order to study these questions, our study aims to collect DNA from blood and tissue samples, where available, to be used for genetic research. Along with DNA, detailed family histories of participants will also be collected to help better understand the genetic causes of prostate cancer . Who is conducting the study? The study is being led by William J. Catalona, M.D. and Misop Han, M.D. and their research team. Drs. Catalona and Han are Co-Directors of Northwestern Memorial Hospital’s Familial Prostate Cancer Screening Program at the Robert H. Lurie Comprehensive ...

MJA • Volume 181 Number 4 • 16 August 2004 213 EBM: TRIALS ON TRIAL The Medical Journal of Australia ISSN: 0025- 729X 16 August 2004 181 4 213 -214 ©The Medical Journal of Australia 2004 www.mja.com.au EBM: Trials on Trial Question Does early detection (by prostate -specific antigen [PSA] testing and digital rectal examination) and treatment of prostate cancer reduce the risk of death from prostate cancer among men aged 45–80 years invited to screening? Trial details Design: Randomised controlled trial. Setting: Population-based study in Quebec City, Canada. Participants: 46193 men aged 45–8 0 ye ars registered on the electoral roll of Quebec City and metropolitan area. Interventions: Invitation to attend annual PSA testing and digital rectal examination to screen for prostate cancer from November 1988 to December 1996. Main ...

W e estimate that 20,500 new cases of prostate cancer and 3,100 deaths will occur in California men in the year 2002. Prostate cancer remains the most fre- quently diagnosed cancer and the second leading cause of cancer -related death among males. The close relationship between aging and cancer is par- ticularly striking with prostate cancer ,which has a median age at diagnosis of 69 years. Prostate cancer rarely occurs before age 40. Incidenc e R a te per 100,000 P opula tion 0 200 400 1000 600 800 1200 1400 1600 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Age Asian/PI Black Hispanic White Prostate Cancer Incidence by Age Group, California, 1995-1999* *Rates are Age-Specific ...

FACTS ABOUT PROSTATE CANCER If you or someone in your family is a man over the age of 45, one of the most important things you can do for yourself, or can recommend to that family member, is to get tested for prostate cancer . Prostate cancer is the most common form of cancer in men. One of every five American men will develop the disease in his lifetime and it is estimated that close to 400,000 new cases of prostate cancer will be detected this year in the United States. The highest incidence of prostate cancer is in North America and northwestern Europe. It is rare in Asia,Africa, Central America, and South America.The way that prostate cancer is distributed among these populations suggests that diet may play a role in the development of this disease, especially if diet affects the level of hormones in men. For reasons that have not yet been identified, ...

Seminar article Hormonal prevention of prostate cancer Otis W. Brawley* Professor of Medicine, Oncology and Epidemiology, The Winship Cancer Institute, Emory University, Atlanta, GA, USA Abstract Prostate cancer is disease in which the mortality rate is highly variable among populations. An increasing risk with migratory changes suggests that some environmental factor or factors influence prostate cancer risk. It is well established that the prostate is hormonally influenced. Carcinogenesis is a process of malignant transformation evolving over time, involving cellular growth and division. There is evidence suggesting that androgenic influences over a period time encourages the process of prostate carcinogenesis. Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for both normal and hyperplastic growth of the prostate gland. ...

wPsrN H,.,r* 9* dtr H*irig x*i.o Wissahickon Hospice One Presidential Blvd. Suite 125 Bala Cynwyd, PA 19004-9927 (610) 617-2400 FAX (610) 617-24Os Medical Guidelines for Determining Appropriateness for Hospice PROSTATE CANCER Patient Name: Diagnosis : Date: INDICATIONS & LI}IITATIONS OF COVERAGEAND/OR MEDICAL NECESSITY The following criteria wiil support a prognosis of six months or less for patients with Prostate Cancer : Basic Criteria: Criteria 1,2, and 3 should be met and Supportive Criteria: . Criteria 4-8 provide supporting evidence List of Criteria - l. Progressive disease: Increasing symptorns and./or decreasing functional stahrs and/or evidence of metastatic disease - 2. Disease Stage: Stage IV (Any T, Any N, M,) at presentation, or progression from an earlier stage of disease to metastatic disease with either of ...

Study one: Calcium has higher risk in case-control Subjects: 526 men with prostate cancer and 536 controls. Method: Case-control study in which dietary intake was compared in the two groups. Results: After controlling for age, family history of prostate cancer , smoking, and total energy and phosphorous intake, those with the higher intakes of calcium had significantly greater risk of having prostate cancer , compared with those with the lower intakes (see table 1). Higher consumption of dairy products was also associated with a greater risk of having prostate cancer . Ref: Cancer Causes Control 1998;9:559-66 Study two: Calcium has extra risk prospectively Subjects: 47,781 men from the Health Professionals Follow-Up Study, apparently free of prostate cancer at the start of the study. Method: Prospective study involving dietary ...

Study one: Toenail selenium and prostate cancer Subjects: 33,737 male health professionals aged 40- 75 years. Method: Case-control study where subjects initially provided toenail clippings, and the incidence of advanced prostate cancer was monitored over the next 7 years. Results: There was a positive association between higher selenium levels and lower risk of advanced prostate cancer . The subjects in the highest quintile of toenail selenium level had half the incidence of prostate cancer compared with the lowest quintile (odds ratio= 0.49; 95% CI 0.25-0.96). Once data were controlled for family history of prostate cancer , body mass index, calcium, lycopene and saturated fat intake, vasectomy, and geographical region, there was a two thirds reduction (odds ratio = 0.35 , 95% CI 0.16-0.78, p = .03). Ref: J Natl Cancer Inst 1998;90:1219-1224 ...

Study one: Carotenes: case control Subjects: 578 men from the Physicians Health Study who had developed prostate cancer during the 13 year follow-up period and 1,294 age- and smoking status- matched controls. Method: Case-control study in which individual carotenes were assayed on the baseline blood sample (alpha-, beta-carotene, beta-cryptoxanthin, lutein, lycopene), together with retinol, and vitamin E. As the original study had been a randomised, placebo- controlled intervention trial involving the giving of aspirin and beta-carotene, the current study group contained both those who had been given beta- carotene supplementation and those who had been given placebo. Results: Lycopene was the only antioxidant found at significantly lower mean levels comparing cases with controls (p = 0.04 for all cases). The results were stronger in the placebo treated group ...